Business World: Biogen Idec, Elan, Tysabri (Natalizumab), and Multiple Sclerosis
Move to Reinstate Multiple Sclerosis Drug
Published: September 21, 2005
By Bloomberg News
Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales of the withdrawn Tysabri drug for multiple sclerosis.
A safety evaluation of the drug for use against Crohn's disease and rheumatoid arthritis will be completed "in the coming weeks," the companies said in a joint statement.
They said that they completed a safety evaluation of the drug for use in multiple sclerosis patients in August.
Biogen, which is based in Cambridge, Mass., and Elan, which is based in Ireland, withdrew Tysabri from the market Feb. 28 after three patients developed a rare neurological disease.
Anthony H. Risser | neuroscience | neuropsychology | brain